RYTM Rhythm Pharmaceuticals, Inc.
$91.97▼ -0.23%
Healthcare
Other
After hours
$91.97▲ +0.00%
Oct 28, 4:56 PM ET
Volume 533.9K
Avg Volume (10D) 510.7K
Key Metrics & Fundamentals
Market Cap
$6.33B
P/E Ratio
–
Div Yield
0.00%
52W Range
74.50 - 122.20
% vs 50 MA
-6.11%
% vs 200 MA
-5.45%
RSI-14
48.8
MACD Histogram
+0.9200
Beta (1Y vs SPY)
1.07
Free Cash Flow
-$9.15M
Gross Rev
$71.26M
Gross Profit
$62.32M
EBITDA
-$44.06M
COGS
$8.93M
Operating Exp
$110.88M
Operating Income
-$48.55M
EBIT
-$48.55M
Pretax Income
-$48.85M
Net Income
-$49.30M
EPS (Diluted)
-0.73
Price & Volume History
Loading chart…
Recent News
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Zacks · Oct 27, 2026 9:00 AM ET
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
Business Wire · Oct 21, 2026 12:30 PM ET
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
GlobeNewswire · Oct 21, 2026 8:00 AM ET
Rhythm Pharmaceuticals Launches Hypothalamic Obesity Treatment in Japan
MT Newswires · Oct 14, 2026 4:32 AM ET
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
GlobeNewswire · Oct 13, 2026 7:30 PM ET
Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know
Zacks · Oct 13, 2026 11:00 AM ET
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Progress In Prader-Willi And Genetically Defined Obesity Therapies
Simply Wall St. · Oct 12, 2026 10:16 PM ET
Prader-Willi Syndrome Market to Expand by 2036 as New Therapeutic Opportunities Address Unmet Clinical Needs | DelveInsight
PR Newswire · Oct 12, 2026 10:31 AM ET
Rhythm's Imcivree Launch in Hypothalamic Obesity Encouraging, RBC Says
MT Newswires · Oct 8, 2026 11:15 AM ET
RBC Lifts Price Target on Rhythm Pharmaceuticals to $159 From $155, Keeps Outperform, Speculative Risk
MT Newswires · Oct 8, 2026 7:46 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See RYTM's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.